Hansa Biopharma

The American Society of Nephrology Kidney Week starts today, and we are excited to participate and hear from experts on latest scientific and medical advances in the field of nephrology. #KidneyWk https://lnkd.in/e5X2-HC

We look forward to attending the annual #congress of the European Society of Gene and Cell Therapy to engage with the clinical and scientific community working at the forefront of innovation in this exciting field. https://lnkd.in/efye-f8c

Hansa Biopharma is looking forward to attending the AMERICAN SOCIETY FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS (ASHI) 50th annual meeting next week and learn about the latest advancements in the field of histocompatibility and transplant immunology. https://lnkd.in/dnxpeuGH?

For investors and media: Today Hansa Biopharma published its interim 2024 #financialreport and Q3 earnings, marking the highest ever quarterly product sales performance and extending the streak of solid strong sales. Highlights include good momentum in clinical trials. Read more on our website: https://lnkd.in/dM-AaQ6N

For investors and media: Today Hansa Biopharma announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company’s next generation IgG-cleaving molecule. The analysis demonstrated that HNSA-5487 can robustly and very rapidly reduce IgG levels, has redosing potential, and a favorable safety and tolerability profile. The Company will focus initial clinical development in diseases where IgG plays a role in disease pathology, including autoimmune conditions, and where the need for management of repeat immune system attacks is crucial. Read more in the press release: https://lnkd.in/d5ek5eRm

On September 11, Hansa Biopharma’s President and CEO Soren Tulstrup will participate in a Fire side chat at H.C. Wainwright & Co. Economics, Inc. 26th Annual Global Investment Conference providing an update on Hansa’s clinical stage programs, recent performance and upcoming milestones. https://lnkd.in/drUMe6iT

Today is world #organdonationday recognizing the gift of organ donation and celebrating those who save lives by being donors. There remains a high unmet need of donor organs, including kidneys. The challenge of finding a compatible organ is even greater for people with complex immunological profiles, specifically those who are considered highly sensitized who face significantly longer waiting time on #transplant waiting list. At Hansa Biopharma, we are committed to helping create more equitable access to transplantation care for highly sensitized people waiting for a kidney transplant. https://lnkd.in/dxjMeP8m

For investors and media: Today Hansa Biopharma published its interim 2024 #financial report and Q2 #earnings. The company has had three consecutive quarters of strong sales and continues to progress key clinical trials in autoimmune, gene therapy and transplantation. Read more on our website: https://lnkd.in/gRpZ8eJT

We are pleased to see the strides made at the High-Level Conference on Organ Donation and Transplantation in Budapest last week, as the EU Presidency advances it efforts to improve #equity in #organdonation and #transplantation across Europe. At Hansa Biopharma we are committed to creating more equitable access to #transplantation care for those considered highly sensitized through a multi-stakeholder approach across the healthcare continuum to ensure correct prioritization, access to innovative treatment options, and healthcare policies modernization. Read more here: https://lnkd.in/dxjMeP8m

Fostering #collaboration and knowledge sharing accelerates #innovation and improves patient outcomes. https://lnkd.in/daEdhuu6 At Hansa Biopharma we are committed to deliver lifesaving and life-altering medicines to people with high medical unmet needs. A key component to delivering on this commitment is our collaborations with the clinical, research, payer and patient communities.